Generex Biotechnology Corporation (NASDAQ: GNBT), a biopharmaceutical company, has a diversified product portfolio designed to deliver innovative products to treat patients with cancer. DNA/RNA-based Medicines and Small Molecules are the two major programs that anchor the Company’s research platform. Ganite® (gallium nitrate injection) is the company’s leading drug in the Small Molecule program. Ganite is exclusively marketed in the U.S. to treat symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. For further information, visit the Company’s web site at www.genta.com.
- 16 years ago
QualityStocks
Generex Biotechnology Corporation (NASDAQ: GNBT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Nightfood Holdings Inc. (NGTF) Leading Hospitality Tech Revolution with Innovative Solutions
Nightfood Holdings (OTCQB: NGTF) is modernizing the hospitality industry with its AI-driven robotics solutions and innovative…
-
QualityStocksNewsBreaks – SolarBank Corp.’s (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Vision in Action: Building the Grid of Tomorrow
Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a…
-
QualityStocksNewsBreaks – ROTH Conference Marks a Quarter-Century of Community in Dana Point
The 37th Annual ROTH Conference drew thousands of participants from around the globe to Dana…